Aclaris Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Aclaris Therapeutics, Inc. (ACRS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $34.68 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-08
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $34.68M.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$39.85M, a 422.04% decline year-over-year.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $27.35M.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $9.03M, a 51.66% decline year-over-year.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$9.97M, a 149.06% decline from fiscal 2016.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $20.32M.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$906.00K, a 177.50% decline from fiscal 2014.
- Aclaris Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $1.17M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $34.68M 10-Q · filed 2018-05-08 | -$5.17M derived: sum of 2 quarters · filed 2018-05-08 | $22.17M derived: sum of 3 quarters · filed 2018-05-08 | $31.20M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | -$39.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$12.51M derived: sum of 2 quarters · filed 2018-03-12 | -$3.48M derived: sum of 3 quarters · filed 2018-03-12 | -$9.97M 10-K · filed 2018-03-12 |
| 2017-09-30 | $27.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $36.38M derived: sum of 2 quarters · filed 2017-11-07 | $29.88M 10-Q · filed 2017-11-07 | $42.26M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $9.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.54M 10-Q · filed 2017-08-08 | $14.91M derived: sum of 3 quarters · filed 2018-05-08 | $893.00K derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | -$6.49M 10-Q · filed 2018-05-08 | $5.88M derived: sum of 2 quarters · filed 2018-05-08 | -$8.14M derived: sum of 3 quarters · filed 2018-05-08 | $10.55M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$1.64M derived: sum of 2 quarters · filed 2018-03-12 | $17.04M derived: sum of 3 quarters · filed 2018-03-12 | $20.32M 10-K · filed 2018-03-12 |
| 2016-09-30 | -$14.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $4.67M derived: sum of 2 quarters · filed 2017-11-07 | $7.95M 10-Q · filed 2017-11-07 | -$7.62M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $18.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $21.96M 10-Q · filed 2017-08-08 | $6.40M derived: sum of 3 quarters · filed 2018-03-12 | $21.96M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $3.28M 10-Q · filed 2017-05-09 | -$12.29M derived: sum of 2 quarters · filed 2018-03-12 | $3.28M derived: sum of 3 quarters · filed 2018-03-12 | $4.66M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | -$15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$2.00K derived: sum of 2 quarters · filed 2018-03-12 | $1.38M derived: sum of 3 quarters · filed 2018-03-12 | -$906.00K 10-K · filed 2018-03-12 |
| 2015-09-30 | $15.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $16.95M derived: sum of 2 quarters · filed 2016-11-03 | $14.66M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$904.00K 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | -$2.29M 10-Q · filed 2016-05-11 | |||
| 2014-12-31 | $1.17M 10-K · filed 2017-03-15 | |||
| 2013-12-31 | -$9.46M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |